

OR Lung Decline Resulting in Transplant

Sam Popa, BS, HDS-C

NATCO August 10, 2018 13:15





The EVLP System used to assess the lungs in this case study is currently undergoing clinical investigation in the United States as part of a clinical trial PXUS 14-001 (NCT02234128).


The study is sponsored by Lung Bioengineering, a wholly owned subsidiary of United Therapeutics Corporation.

The system is for investigational use only.




- According to Organ Procurement and Transplantation Network (OPTN) data, in 2017, the national lung utilization rate was 23.7%
- Lungs declined in the donor operating room often have little to no opportunity for reallocation due to time constraints on the recipient transplant centers and unacceptable cold ischemic times.
- Ex Vivo Lung Perfusion (EVLP) may allow an Organ Procurement Organization (OPO) extended time to allocate lung(s) to a center beyond the time of the deceased donor cross clamp time.

HOW DOES OUR STUDY WORK?









*Time allowed
by trial
protocol*


CIT-1	EVLP	CIT-2
 10 h	 3-6 h	 6 h
Donor cross clamp to EVLP start	Normothermic Perfusion	EVLP end to start of transplant procedure












ACTIVATED CLINICAL TRIAL SITES



The background of the slide is a photograph of two pig lungs in a laboratory setting. The lungs are pinkish-brown and are connected to a network of clear plastic tubes and mechanical equipment. The scene is dimly lit, with some blue light visible. A solid blue horizontal band with a fine white diagonal line pattern runs across the middle of the image, serving as a background for the "THANK YOU" text.

THANK YOU